Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.
Trial Details
- NCT ID
- NCT07244406
- Phase
- PHASE2
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Locations (sample)
- Beijing, China|39.9075,116.39723
Key Eligibility Criteria
- Sign the informed consent and be willing and able to comply with the visit, treatment regimen, laboratory examination and other requirements of the…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →